Post by
subaru1i on Apr 05, 2024 12:09pm
When it comes to an ROFR, the end game boils down to who
has the deepest pockets, the non ROFR holder having the ability to out bid the ROFR holder.
TEVA is big into advanced cannabis pharmaceuticals, including payload delivery structures and targeting mechanisms but so if Pfizer.
The best the non-winner could do is suddenly accumulate a large block of stock to at least leverage a seat on the board of directors....a real thorn in the winners side.